Friday, February 20, 2009

Introducing OraVerse‏

Novalar Pharmaceuticals™ is pleased to introduce OraVerse™ (phentolamine mesylate) Injection, the first and only local anesthesia reversal agent. In conjunction with exhibiting at the Chicago Dental Society Midwinter Meeting, Novalar will be releasing product information to the dental and business media on February 27. Since our primary focus and commitment is to the dental practitioner, Novalar is providing you this advance notice. The company has experienced significant interest in the product from the media following previous announcements, and news about OraVerse may reach the attention of consumers. You may receive questions about OraVerse from some of your patients so we hope you will take this opportunity to learn more about OraVerse.

OraVerse is a local anesthesia reversal agent that accelerates the return to normal sensation and function for patients who want to avoid the unwanted and unnecessary lingering soft tissue numbness after routine dental procedures. OraVerse has been proven safe and effective for adults and children 6 and older and weighing more than 33 lbs. in nationwide clinical trials. Patients that received OraVerse experienced a return to normal sensation and function in approximately half the time.1,2 OraVerse comes in a standard dental cartridge and is administered in a 1:1 ratio to local anesthetic (up to 2 cartridges).

No comments: